Table 1 Description of overall study participants’ demographics, COVID-19 vaccination intention, and vaccine characteristics influencing vaccination acceptance and vaccine choice
Participants n = 19,714 n (%) | Weighted prevalence % (95 CI) | ||
|---|---|---|---|
Socio demography | |||
Age group, years | |||
18–29 | 5233 (26.5) | 38.4 (37.1–39.6) | |
30–39 | 5524 (28.0) | 25.4 (24.3–26.6) | |
40–49 | 4070 (20.6) | 16.3 (15.4–17.2) | |
50–59 | 2751 (14.0) | 12.0 (11.2–12.9) | |
60 and above | 2136 (10.8) | 7.9 (7.3–8.5) | |
Gender | |||
Male | 9145 (46.4) | 46.1 (44.8–47.4) | |
Female | 10,557 (53.6) | 53.8 (52.5–55.1) | |
Other | 12 (0.1) | 0.1 (0.1–0.2) | |
Highest education level | |||
Secondary school and below | 2630 (13.3) | 12.0 (11.2–12.9) | |
Certificate/A-Level/Diploma | 4856 (24.6) | 22.3 (21.2–23.4) | |
Bachelor degree | 7883 (40.0) | 42.5 (41.2–43.8) | |
Postgraduate degree | 4345 (22.0) | 23.2 (22.2–24.4) | |
WHO regiona | |||
African | 1086 (5.5) | 1.3 (1.3–1.3) | |
Eastern Mediterranean | 4122 (20.9) | 7.1 (7.1–7.1) | |
European | 2403 (12.2) | 1.9 (1.9–1.9) | |
Region of the Americas | 968 (4.9) | 8.5 (8.5–8.5) | |
South-east Asia | 3436 (17.4) | 36.4 (36.4–36.4) | |
Western Pacific | 7699 (39.1) | 44.8 (44.8–44.8) | |
Ever delayed acceptance or refuse vaccine despite availability of vaccine service | |||
Yes | 3812 (19.3) | 18.0 (17.1–19) | |
No | 15,902 (80.7) | 82.0 (81–82.9) | |
COVID-19 vaccine acceptance | |||
Extremely likely | 8395 (42.6) | 47.2 (45.9–48.4) | |
Likely | 8800 (44.6) | 43.2 (41.9–44.5) | |
Unlikely | 1933 (9.8) | 6.9 (6.3–7.4) | |
Extremely unlikely | 586 (3.0) | 2.8 (2.5–3.1) | |
Vaccine characteristics influencing vaccination acceptance | |||
Required doses of COVID-19 vaccine | |||
Only accept single dose | 8025 (40.7) | 37.6 (36.4–38.8) | |
Do not mind | 11,689 (59.3) | 62.4 (61.2–63.6) | |
Effectiveness threshold of COVID-19 vaccine | |||
Only accept 90% threshold | 12,625 (64.0) | 59.7 (58.4–61.0) | |
Do not mind | 7089 (36.0) | 40.3 (39.0–41.6) | |
Adverse reactions of COVID-19 vaccine | |||
Only accept minor adverse reactions | 14,002 (71.0) | 74.5 (73.4–75.5) | |
Do not mind moderate adverse reactions | 5712 (29.0) | 25.5 (24.5–26.6) | |
Duration of COVID-19 vaccine protection | |||
Only accept no lesser than 12 months | 11,452 (58.1) | 53.3 (52.0–54.6) | |
Do not mind | 8262 (41.9) | 46.7 (45.4–48.0) | |
Technology used in COVID-19 vaccine | |||
Do not accept mRNA technology | 4030 (20.4) | 21.0 (20.0–22.0) | |
Do not mind | 6144 (31.2) | 34.0 (32.7–35.2) | |
Do not know much about mRNA technology | 9540 (48.4) | 45.1 (43.8–46.3) | |
Producing country of COVID-19 vaccine | |||
Only accept a vaccine that is produced by specific countries | 11,919 (60.5) | 51.8 (50.5–53.1) | |
Producing countries of a COVID-19 vaccine is not of my concern in vaccine acceptance | 7795 (39.5) | 48.2 (46.9–49.5) | |
First foremost important vaccine characteristics influencing COVID-19 vaccine choice | |||
Effectiveness threshold | 7719 (39.2) | 35.1 (30.1–40.5) | |
Adverse reactions | 6387 (32.4) | 40.6 (33.2–48.4) | |
Duration of protection | 1748 (8.9) | 8.7 (7.5–9.9) | |
Administration doses | 1423 (7.2) | 7.2 (5.1–10.2) | |
Country of origin | 907 (4.6) | 3.4 (1.9–5.8) | |
Vaccination cost | 861 (4.4) | 2.5 (1.0–6.1) | |
mRNA technology | 639 (3.2) | 2.5 (1.7–3.7) | |
Second important vaccine characteristics influencing COVID-19 vaccine choice | |||
Adverse reactions | 5140 (26.1) | 24.2 (17.8–31.9) | |
Duration of protection | 4630 (23.5) | 29.0 (24.8–33.5) | |
Effectiveness threshold | 3729 (18.9) | 22.5 (18.3–27.4) | |
Country or origin | 2907 (14.7) | 9.3 (4.5–17.9) | |
Cost of vaccination | 1428 (7.2) | 4.1 (1.7–9.6) | |
Administration doses | 1230 (6.2) | 7.1 (6.0–8.3) | |
mRNA technology | 589 (3.0) | 3.9 (3.3–4.6) | |